<DOC>
	<DOCNO>NCT00004238</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness 10-propargyl-10-deazaaminopterin treating patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>10-Propargyl-10-Deazaaminopterin Treating Patients With Stage IIIB Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate , duration response , time disease progression patient stage IIIB ( pleural pericardial disease ) stage IV non-small cell lung cancer treat 10-propargyl-10-deazaaminopterin first line second line chemotherapy . II . Determine toxicity drug patient population . III . Determine duration survival patient . IV . Determine quality life patient . OUTLINE : Patients receive 10-propargyl-10-deazaaminopterin IV day 1 15 . Treatment repeat every 4 week absence unacceptable toxicity disease progression . Quality life assess begin course . Patients follow every 8 week disease progression . PROJECTED ACCRUAL : A total 19-39 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIIB ( pleural pericardial disease ) stage IV nonsmall cell lung cancer Measurable evaluable indicator lesion irradiate Pleural effusion , bone metastasis , brain metastasis , elevate serum enzyme , abnormal radionucliotide scan unacceptable sole indicator lesions No clinically significant pleural effusion ascites No grade III IV edema No prior pneumonectomy No symptomatic uncontrolled brain leptomeningeal involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 Hemoglobin least 10 g/dL Platelet count least 160,000/mm3 Hepatic : Bilirubin great 1.0 mg/dL AST great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 5 time ULN Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : No unstable cardiac disease require treatment Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent active cancer No history significant neurologic psychiatric disorder , include psychotic disorder , dementia , seizures No active uncontrolled infection No serious illness medical condition PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy OR Progression stable disease initial response 1 prior chemotherapy regimen , include 1 preoperative adjuvant chemotherapy regimen Endocrine therapy : Concurrent steroid allow dose stable Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy Surgery : See Disease Characteristics Other : No prior antifolates At least 7 day since prior folic acid supplement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>